Epividian Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Epividian's estimated annual revenue is currently $2.5M per year.(i)
  • Epividian's estimated revenue per employee is $101,500

Employee Data

  • Epividian has 25 Employees.(i)
  • Epividian grew their employee count by 9% last year.

Epividian's People

NameTitleEmail/Phone
1
Director, IT Systems and Security & Security OfficerReveal Email/Phone
2
Director Data Management, Quality and ReportingReveal Email/Phone
3
Associate Director, Data IntegrationsReveal Email/Phone
4
Director Data Management and ReportingReveal Email/Phone
5
Senior Director EpidemiologyReveal Email/Phone
6
Associate Director EpidemiologyReveal Email/Phone
7
Senior Clinical Support AnalystReveal Email/Phone
8
UI/UX DesignerReveal Email/Phone
9
Principal Full Stack EngineerReveal Email/Phone
10
Product AnalystReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.4M6N/AN/AN/A
#2
$1.7M190%N/AN/A
#3
$11.2M7754%N/AN/A
#4
$0.6M8-20%N/AN/A
#5
$0.4M6N/AN/AN/A
#6
$2M20-9%N/AN/A
#7
$0.9M100%N/AN/A
#8
$0.9M10-29%N/AN/A
#9
$0.7M9-10%N/AN/A
#10
$5.1M442%N/AN/A
Add Company

What Is Epividian?

Epividian advances the mission of medicine by empowering and providing novel research services for clinical practice, clinical research, academic, public health and regulatory purposes. Our unique approach combines real world clinical data throughout the medical ecosystem from clinical research to clinical application. Point-of-care observational data from the doctor-patient encounter is used to support real-world medical research. Our mission is the mission of medicine: solving complex problems to improve the health of individuals and the public. The OPERA® database and research network (Observational Pharmaco-Epidemiology Research & Analysis) is a multi-site observational database built from the complete patient health records managed in Electronic Health Record (EHR) systems from more than 400 participating caregivers across 54 cities throughout the U.S. These physicians and other healthcare workers have documented the care of nearly 930,000 patients in these EHRs, including 93,000 patients who are HIV positive, representing about 8% of all the HIV+ patients linked to care in the U.S. The OPERA® database is refreshed from these EHR databases at each clinic on a daily basis, making the OPERA® database the largest continuously operating cohort of HIV+ patients in the U.S. Epividian provides these clinicians with a variety of meaningful analytical reports and research services supporting the day-to-day care of patients and the management of their patient population. Because these clinicians are not only sharing data but also are regular consumers of the CHORUS™ practice reports, all parties have a vested interest in maintaining the completeness and accuracy of the medical records stored in the EHR systems. Additionally, some of the clinicians in the network also utilize the OPERA® database for identifying candidates for clinical trials they are conducting and/or using the database for various non-interventional studies and papers. Epividian is dedicated to improving health outcomes. Using longitudinal observational data gathered from clinical encounters, Epividian enables and facilitates sophisticated interventional and non-interventional research. Through our longitudinal observational database research engine and our CHORUS service, Epividian is committed to: - Enhancing the doctor-patient relationship by helping doctors spend more time with patients and less time on report generation - Protecting and alerting patients from and about possible side effects through constant data monitoring - Bridging the gap between clinical medicine and clinical research - Improving public health and understanding the impact of interventions

keywords:N/A

N/A

Total Funding

25

Number of Employees

$2.5M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.7M25-7%N/A
#2
$4.7M2519%N/A
#3
$3.2M2519%N/A
#4
$3.9M25-31%N/A
#5
$4.5M260%N/A